<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="107624">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01962363</url>
  </required_header>
  <id_info>
    <org_study_id>EPI-743 PM</org_study_id>
    <nct_id>NCT01962363</nct_id>
  </id_info>
  <brief_title>EPI-743 in Friedreich's Ataxia Point Mutations</brief_title>
  <official_title>A Phase 2A Clinical Trial of EPI-743 (Vincerinoneâ„¢) on Visual Function in Friedreich's Ataxia Patients With Point Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of South Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Edison Pharmaceuticals Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Friedreich's Ataxia Research Alliance</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of South Florida</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of EPI-743 in patients with
      Friedreich's Ataxia point mutations
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Visual function</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Low contrast acuity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety parameters</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Clinical and laboratory safety parameters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual function</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Visual fields as assessed by Humphrey 30-2 exam; High contrast visual acuity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurologic function</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Friedreich's Ataxia Rating Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical function</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>25-foot walk (for subjects capable of completing the test on enrollment);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patient report via rating scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activities of Daily Living</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patient report via rating scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac indices</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Echocardiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Upper extremity function</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>9 hole peg test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease biomarkers</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Glutathione cycle components</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">4</enrollment>
  <condition>Friedreich's Ataxia Point Mutation</condition>
  <arm_group>
    <arm_group_label>EPI-743</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EPI-743, oral, 400mg three times daily for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPI-743</intervention_name>
    <arm_group_label>EPI-743</arm_group_label>
    <other_name>Vincerinone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of genetically confirmed Friedreich's ataxia point mutation.

          2. Visual acuity at baseline more than 15 letters on high contrast EDTRS at four meters.

          3. FARS score of 20 to 90.

          4. Male or female between 18 and 65 years of age.

          5. Agreement to use contraception if within reproductive years

          6. Hormone replacement therapy, if used, must remain stable for the duration of the
             study.

          7. Willingness and ability to comply with study procedures.

          8. Willingness and ability to arrive at study site metropolitan area day prior to
             evaluations.

          9. Abstention from use of dietary supplements and non-prescribed medications at least 30
             days prior to initiation of treatment and for the duration of the study. This would
             specifically include idebenone, Coenzyme Q10 and vitamin E.

         10. Abstention from foods or beverages or bars fortified with Coenzyme Q10, vitamin E,
             super fortified functional foods or beverages at least 30 days prior to initiation of
             treatment and for the duration of the study.

         11. Abstention from use of other investigative or non-approved drugs within 30 days of
             enrollment and for the duration of the study.

         12. Subject can swallow multiple size 0 capsules.

         13. Subject has voluntarily signed an IRB approved informed consent form to participate
             in the study after all relevant aspects of the study have been explained and
             discussed with the subject.

        Exclusion Criteria:

          1. Allergy to EPI-743 or sesame oil or nuts.

          2. Clinically significant bleeding condition or abnormal PT/PTT INR (INR &gt; two; PTT &gt;
             two-times normal).

          3. Liver insufficiency with LFTs greater than three-times upper normal limit at
             screening.

          4. Renal insufficiency with creatinine &gt; 1.5 at screening.

          5. Fat malabsorption syndromes.

          6. Any other respiratory chain diseases of the mitochondria or inborn errors of
             metabolism.

          7. Any other ophthalmologic conditions.

          8. Clinically significant cardiomyopathy with ejection fraction &lt; 40 percent at
             screening.

          9. Clinically significant arrhythmia within past two years requiring treatment.

         10. Surgery planned through the duration of the study, including follow-up.

         11. Pregnancy or breastfeeding.

         12. Anticoagulant therapy within 30 days of enrollment.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kelly Sullivan, PhD</last_name>
    <phone>813-974-5909</phone>
    <email>kbarber@health.usf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kevin Allison, BS</last_name>
    <phone>813-974-5909</phone>
    <email>kalliso1@health.usf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Theresa Zesiewicz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 23, 2013</lastchanged_date>
  <firstreceived_date>October 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Friedreich Ataxia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
